|100 Vanguard Blvd. , Malvern, PA 19355|
|Fund Manager||Justin Schwartz|
|Manager Tenure||5 Years 8 Months|
The Fund seeks to provide current income that is exempt from federal personal income taxes, with limited price volatility. The Fund has no limitations on the maturity of individual securities but is expected to maintain a dollar-weighted average maturity of 1 to 2 years. At least 75% of the securities held by the Fund are municipal bonds in the top three credit-rating categories as determined by a nationally recognized statistical rating organization (NRSRO) (e.g., Aaa, Aa, and A by Moody's Investors Service, Inc. (Moody's)) or, if unrated, determined to be of comparable quality by the advisor. The Fund may invest up to 20% of its assets in medium-grade quality bonds, as determined by an NRSRO (e.g., Baa by Moody's) or by the advisor. The remaining 5% may be invested in securities with lower credit ratings or, if unrated, determined to be of comparable quality by the advisor.
|Asset Type||% Of Allocation|
|Total Net Assets||972.26 M|
|Criteria||3 Years||5 Years||10 Years|
|Minimum Initial IRA||$0|
|Timeframe||Average Annual Current Performance Monthly As Of 09/30/2021||Average Annual Current Performance Quarterly As Of 09/30/2021||Avg Annual Current Performance Monthly As Of 09/30/2021||Avg Annual Current Performance Quarterly As Of 09/30/2021|
|Life Of Fund||
Master The Market with the Help of Our Financial Experts
Upside remains for steelmaker even after key downgrade, as infrastructure spending is still in play in Washington.
Cramer says the clouds over Wall Street may have broken. Get ready for next week's earnings parade.
Internal unrest over content of comedian's latest program continues at streaming giant.
Tether made 'untrue or misleading statements and omissions in connection with the U.S. dollar tether token stablecoin,' the CFTC said.
Virgin Galactic stock had verged on a breakout. Now it's dropping. Here's where we're looking to buy the dip.
Chip foundry makes Taiwan an even bigger target for Beijing's aggressive moves.
Johnson & Johnson shares rose after an FDA advisory panel backed the authorization of boosters for the company's single-shot Covid-19 vaccine.
Moderna shares slip on a report the FDA is delaying a decision to approve the company's COVID-19 vaccine for adolescents.